Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRYSTAL: Ranibizumab PRN Dosing in CRVO
NCT01535261Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Primary completion
- Mar 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of ranibizumab in macular edema, sponsored by Novartis. Started Feb 2012; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01535261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01535261.